

Disclosure Purpose: 21-11462

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
A Randomized Trial of Third Dose mRNA-1273 Vaccine in Transplant Recipients
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-11462

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
A Randomized Trial of Third Dose mRNA-1273 Vaccine in Transplant Recipients
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-11462

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
A Randomized Trial of Third Dose mRNA-1273 Vaccine in Transplant Recipients
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-11462

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Astellas Pharma	Grant / Contract	Self
<i>Recipient Name:</i> Atul <i>Grant / Contract Description:</i> Research support and Education support <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Astellas Pharma	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Advisory
F. Hoffmann-La Roche	Grant / Contract	Self
<i>Recipient Name:</i> Atul Humar, University Health Network <i>Grant / Contract Description:</i> Research Support <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Merck	Grant / Contract	Self
<i>Recipient Name:</i> Atul Humar <i>Grant / Contract Description:</i> Clinical trial for CMV prevention <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Merck	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Advisory Board

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.
- What is the manuscript title?**

A Randomized Trial of Third Dose mRNA-1273 Vaccine in Transplant Recipients
- Are you the corresponding author?**

Yes.

 - Please list the other authors' names here.**

Victoria G. Hall, M.B.B.S. Victor H. Ferreira, Ph.D. Terrance Ku, M.Sc. Matthew Ierullo, M.Sc. Beata Majchrzak-Kita, M.Sc. Cecilia Chaparro, M.D. Nazia Selzner, M.D. Jeffrey Schiff, M.D. Michael McDonald, M.D. George Tomlinson, Ph.D. Vathany Kulasingam, Ph.D. Deepali Kumar, M.D.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-11462

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
A Randomized Trial of Third Dose mRNA-1273 Vaccine in Transplant Recipients
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-11462

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
A Randomized Trial of Third Dose mRNA-1273 Vaccine in Transplant Recipients
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-11462

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Abbott Laboratories	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> provide advice on new assay formulations and changes

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
A Randomized Trial of Third Dose mRNA-1273 Vaccine in Transplant Recipients
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-11462

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
F. Hoffmann-La Roche	Grant / Contract	Self
<i>Recipient Name:</i> University Health Network <i>Grant / Contract Description:</i> Baloxavir vs. Placebo for Treatment of Hospitalized Patients with Influenza		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research <i>Additional Information:</i>
F. Hoffmann-La Roche	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Advisory Fees: Baloxavir in Influenza Infections Use of monoclonal antibody preparations in COVID-19
GlaxoSmithKline	Grant / Contract	Self
<i>Recipient Name:</i> University Health Network <i>Grant / Contract Description:</i> Shingrix Vaccine in Kidney Transplant Recipients Booster Dose of Shingrix Vaccine in Transplant		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research <i>Additional Information:</i>
GlaxoSmithKline	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Advisory Fees for Shingrix Vaccine in Immunocompromised Populations
Merck	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Consultancy and Advisory Board
Pfizer	Other	Self
<i>Category:</i> Other <i>Additional Information:</i>		<i>Description:</i> Advisory Board - Pneumococcal Conjugate Vaccine
SANOFI PASTEUR INC.	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Advisory Fees: Influenza Vaccine Advisory Board

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
 No.
- What is the manuscript title?**
 A Randomized Trial of Third Dose mRNA-1273 Vaccine in Transplant Recipients
- Are you the corresponding author?**
 No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-11462

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
"A Randomized Trial of Third Dose mRNA-1273 Vaccine in Transplant Recipients,"
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-11462

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
A randomized trial of third dose mRNA-1273 vaccine in transplant recipients
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-11462

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Novartis	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> 2 hour round table discussion of an immunosuppressive agent in development.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
A Randomized Trial of Third Dose mRNA-1273 Vaccine in Transplant Recipients
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-11462

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
A Randomized Trial of Third Dose mRNA-1273 Vaccine in Transplant Recipients
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-11462

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
A Randomized Trial of Third Dose mRNA-1273 Vaccine in Transplant Recipients
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

